The Omnipod 5 will be immediately available for people ages 6 to 70. A new technology for people with Type 1 diabetes, one that has been nearly a decade in the making, has been approved by the U.S.

ABSTRACTObjectives: Continuous subcutaneous insulin infusion (CSII), or “insulin pump” therapy, is an alternative to multiple daily insulin injections (MDII) for management of diabetes. This study ...

AID systems combine an insulin pump with a continuous glucose monitor to automatically adjust insulin levels throughout the ...

All patients said insulin pump therapy helped their diabetes management related to exercise. Older patients with type 1 diabetes (T1D) appear to benefit from insulin pumps and continuous glucose ...

The FDA has cleared its first automated insulin pump for adults with Type 2 diabetes, with Insulet’s Omnipod 5 delivery system opening the door to a population of more than 6 million people. That ...

While insulin pumps and continuous glucose monitors have improved the lives of many Type ...

Embecta has secured an FDA clearance for its first wearable insulin delivery system, with a patch pump designed for people with either Type 1 or Type 2 diabetes. The fully disposable device includes a ...

Type 1 diabetes is more prevalent in Finland than anywhere else in the world, affecting approximately 50,000 people. New automated insulin delivery pumps have significantly improved diabetes care, ...

Insulin pumps are the most advanced insulin delivery technology available today for people with type 1 and type 2 diabetes. An insulin pump replaces injections with a syringe or insulin pen, using an ...

Please provide your email address to receive an email when new articles are posted on . We were unable to process your request. Please try again later. If you continue to have this issue please ...

Most of the 38 million people living with diabetes in the U.S. use daily injections or insulin pumps to keep glucose at safe levels — but new research suggests that a third option could be just as ...

Youth with type 1 diabetes who use real-time continuous glucose monitoring (rtCGM) and an insulin pump spend more time in target glucose range than those using intermittently scanned CGM (isCGM) ...